Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 8/20 | 0.72 |
| ▸ | LMNA | P02545 | 2/20 | 0.72 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | AR | P10275 | 1/20 | 0.49 |
| ▸ | KIF11 | P52732 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | IKBKB | O14920 | 1/20 | 0.48 |
| ▸ | PTPRB | P23467 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9490752 | 0.98 | HPGD (0.70) | HPGDLMNAHTTSMN1; SMN2NR3C2 | |
| SCHEMBL3555917 | 0.92 | HPGD (0.62) | HPGDLMNAHTTSMN1; SMN2NR3C2 | |
| SCHEMBL3559068 | 0.87 | HPGD (0.59) | HPGDLMNAHTTTSHRHSD17B10 | |
| SCHEMBL9489980 | 0.87 | HPGD (0.57) | HPGDLMNAHTTSMN1; SMN2CA12 | |
| SCHEMBL9514803 | 0.85 | HPGD (0.69) | HPGDLMNAHTTSMN1; SMN2NR3C2 | |
| SCHEMBL8231736 | 0.84 | THRA (0.59) | HPGDLMNASMN1; SMN2AR | |
| SCHEMBL16051464 | 0.83 | THRA (0.65) | HPGDLMNASMN1; SMN2AR | |
| SCHEMBL7861945 | 0.83 | HPGD (0.67) | HPGDLMNAHTTSMN1; SMN2NR3C2 | |
| SCHEMBL457811 | 0.83 | HPGD (0.67) | HPGDLMNAHTTSMN1; SMN2NR3C2 | |
| SCHEMBL894869 | 0.82 | THRA (0.64) | HPGDLMNATSHRAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132500-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | ARRAY BIOPHARMA INC (US) | 2024-04-25 | — | — | US | disclosed |
| US-20240116872-A1 | PYRIDYL INHIBITORS FOR HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2024-04-11 | — | — | US | disclosed |
| US-20230265054-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2023-08-24 | — | — | US | disclosed |
| US-20230234955-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | ARRAY BIOPHARMA INC (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230143250-A1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2023-05-11 | — | — | US | disclosed |
| EP-3661935-B1 | SUBSTITUTED PYRAZOLOPYRIMIDINES USEFUL AS KINASES INHIBITORS | TELIGENE LTD (CN) | 2022-10-12 | — | — | EP | disclosed |
| US-11344553-B2 | Substituted pyrazolopyrimidines useful as kinases inhibitors | TELIGENE LTD. (CN) | 2022-05-31 | — | — | US | disclosed |
| US-11344553-B2 | Substituted pyrazolopyrimidines useful as kinases inhibitors | TELIGENE LTD. (CN) | 2022-05-31 | — | — | US | disclosed |
| US-11267818-B2 | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds | ARRAY BIOPHARMA INC. (US) | 2022-03-08 | — | — | US | disclosed |
| EP-3372605-B1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2021-11-03 | — | — | EP | disclosed |
| WO-2009126863-A2 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2009-10-15 | — | — | WO | disclosed |
| WO-2007144379-A1 | BICYCLIC COMPOUNDS USEFUL AS CATHEPSIN S INBHIBITORS | MEDIVIR AB (SE) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007144379-A1 | BICYCLIC COMPOUNDS USEFUL AS CATHEPSIN S INBHIBITORS | MEDIVIR AB (SE) | 2007-12-21 | — | — | WO | disclosed |
| EP-1789390-A2 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | Genentech, Inc. (US) | 2007-05-30 | — | — | EP | disclosed |
| US-20060063779-A1 | Pyridyl inhibitors of hedgehog signalling | CURIS ROYALTY LLC | 2006-03-23 | — | — | US | disclosed |
| WO-2006028958-A2 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2006-03-16 | — | — | WO | disclosed |
| EP-0324791-B1 | ARYL-N-AMINOALKYL-4-(SULFONAMIDO)BENZAMIDES, ANTIARRHYTMIC AGENTS AND COMPOSITIONS THEREOF | SCHERING AKTIENGESELLSCHAFT (DE) | 1993-03-24 | — | — | EP | disclosed |
| US-4920116-A | ANTIARRHYTHMIA AGENTS | SCHERING A.G. (DE) | 1990-04-24 | — | — | US | disclosed |
| EP-0324791-A1 | ARYL-N-AMINOALKYL-4-(SULFONAMIDO)BENZAMIDES, ANTIARRHYTMIC AGENTS AND COMPOSITIONS THEREOF. | SCHERING AG (DE) | 1989-07-26 | — | — | EP | disclosed |
| WO-1988002362-A1 | ARYL-N-AMINOALKYL-4-(SULFONAMIDO)BENZAMIDES, ANTIARRHYTMIC AGENTS AND COMPOSITIONS THEREOF | SCHERING AKTIENGESELLSCHAFT (DE) | 1988-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11267818-B2 | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds | TYMP, TYMS, P2RX7 | HPGD 1501/4885LMNA 3016/4885HTT 1545/4885 |
| US-20230143250-A1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF | HSD17B1, HSD17B13, HSD17B3 | HPGD 43/4885LMNA 2111/4885HTT 3705/4885 |
| US-20240132500-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | TYMP, TYMS, P2RX7 | HPGD 1501/4885LMNA 3016/4885HTT 1545/4885 |
| US-20230265054-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | SHH, GLI1, SMO | HPGD 2728/4885LMNA 3716/4885HTT 2919/4885 |
| US-20240116872-A1 | PYRIDYL INHIBITORS FOR HEDGEHOG SIGNALLING | SHH, GLI1, SMO | HPGD 2664/4885LMNA 3718/4885HTT 2943/4885 |
| US-20230234955-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | TYMP, TYMS, TK1 | HPGD 1016/4885LMNA 2889/4885HTT 1956/4885 |
| US-20060063779-A1 | Pyridyl inhibitors of hedgehog signalling | SHH, GLI1, SMO | HPGD 2728/4885LMNA 3716/4885HTT 2919/4885 |
| US-11344553-B2 | Substituted pyrazolopyrimidines useful as kinases inhibitors | MAP3K20, PRKDC, MAP3K6 | HPGD 2080/4885LMNA 3778/4885HTT 3246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.